Retrospective population-based assessment of medically attended injection site reactions, seizures, allergic responses and febrile episodes after acellular pertussis vaccine combined with diphtheria and tetanus toxoids
- 1 August 2002
- journal article
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 21 (8) , 781-786
- https://doi.org/10.1097/00006454-200208000-00016
Abstract
Since 1997 diphtheria-tetanus toxoids-acellular pertussis (DTaP) vaccines have been recommended for the five dose pertussis vaccination series. To assess rates of medically attended injection site reactions (ISRs), seizures, allergic responses and febrile episodes after Tripedia DTaP vaccine administered in the context of routine care, we conducted a retrospective assessment among the population of Group Health Cooperative from 1997 through 2000. Administrative databases were used to identify medical visits linked with diagnostic codes potentially indicative of ISRs, seizures, allergic responses and febrile episodes after DTaP vaccine. Outcomes were confirmed by medical record review. During the study period 76 133 doses of DTaP were administered. Of the 26 ISRs identified, 6 followed DTaP given as the fourth dose and 18 followed DTaP given as the fifth dose, for rates of 1 per 2779 and 1 per 900 vaccinations, respectively. During the study period nearly all children receiving DTaP as the fifth dose had received whole cell pertussis vaccine for their primary series, and all of the fifth dose ISRs were among that group. Four of those reactions involved the entire upper arm. The rate of febrile seizures within 2 days of DTaP among children <2 years of age was 1 per 19 496 vaccinations. The low rate of febrile seizures and other serious events confirms the safety of DTaP vaccine. The risk of medically attended ISRs was highest with DTaP given as the fifth dose, and whole arm reactions were reported, but medically attended ISRs were relatively uncommon and were self-limited.Keywords
This publication has 21 references indexed in Scilit:
- Combination Vaccines: Postlicensure Safety EvaluationClinical Infectious Diseases, 2001
- Safety and immunogenicity of Biken acellular pertussis vaccine in combination with diphtheria and tetanus toxoid as a fifth dose at four to six years of ageThe Pediatric Infectious Disease Journal, 2001
- Reactogenicity and Immunogenicity at Preschool Age of a Booster Dose of Two Three-Component Diphtheria-Tetanus-Acellular Pertussis Vaccines in Children Primed in Infancy With Acellular VaccinesPediatrics, 2001
- Infant Immunization With Acellular Pertussis Vaccines in the United States: Assessment of the First Two Years' Data From the Vaccine Adverse Event Reporting System (VAERS)Published by American Academy of Pediatrics (AAP) ,2000
- Acellular Pertussis Vaccine: Recommendations for Use as the Initial Series in Infants and ChildrenPediatrics, 1997
- Clinical experience of a tricomponent acellular pertussis vaccine combined with diphtheria and tetanus toxoids for primary vaccination in 22,505 infantsThe Journal of Pediatrics, 1996
- A Controlled Trial of a Two-Component Acellular, a Five-Component Acellular, and a Whole-Cell Pertussis VaccineNew England Journal of Medicine, 1996
- A Controlled Trial of Two Acellular Vaccines and One Whole-Cell Vaccine against PertussisNew England Journal of Medicine, 1996
- Acellular pertussis vaccine as a booster dose for seventeen- to nineteen-month-old children immunized with either whole cell or acellular pertussis vaccine at two, four and six months of ageThe Pediatric Infectious Disease Journal, 1995
- Comparison of an acellular pertussis-component diphtheria-tetanus-pertussis (DTP) vaccine with a whole-cell pertussis-component DTP vaccine in 17- to 24-month-old children, with measurement of 69-kilodalton outer membrane protein antibodyThe Journal of Pediatrics, 1990